Enhanced prostaglandin biosynthesis in human gingival fibroblasts isolated from patients treated with phenytoin.
Prostaglandin E2 (PGE2) formation was studied in human gingival fibroblasts derived from three epileptic patients before and after 9 months of phenytoin (PHT) therapy. Interleukin 1 (IL-1 alpha; 0.3-6.0 ng/ml), (IL-1 beta; 10-1000 pg/ml) and tumour necrosis factor (TNF alpha; 0.01-0.1 microgram/ml) dose-dependently stimulated the formation of PGE2 in 24 h cultures. In fibroblasts, derived after 9 months of PHT therapy, IL-1 alpha, IL-1 beta and TNF alpha induced a significantly higher formation of PGE2 compared to that in fibroblasts derived before PHT therapy. IL-1 beta induced a significantly higher release also of 3H-arachidonic acid (3H-AA) from prelabelled PHT fibroblasts compared to that in prelabelled gingival fibroblasts isolated before the drug therapy. Addition of exogenous AA caused a spontaneous increase of PGE2 formation in PHT fibroblasts compared to that in fibroblasts isolated before the PHT treatment. The results indicate that PHT medication results in an upregulation of prostanoid formation in gingival fibroblasts partly due to an increased phospholipase A2 activity and partly due to an increased cyclooxygenase activity.
Modéer
T
T
Department of Pedodontics, Karolinska Institute, Huddinge, Sweden.
Andurén
I
I
Lerner
U H
UH
D015121:6-Ketoprostaglandin F1 alpha / Q000096:biosynthesis; D001095:Arachidonic Acids / Q000493:pharmacokinetics / Q000494:pharmacology; D002478:Cells, Cultured; D002648:Child; D015232:Dinoprostone / Q000096:biosynthesis*; D004305:Dose-Response Relationship, Drug; D004827:Epilepsy / Q000188:drug therapy; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism*; D005881:Gingiva / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D005885:Gingival Hyperplasia / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology; D005891:Gingivitis / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology; D010672:Phenytoin / Q000009:adverse effects*; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D015854:Up-Regulation
D001095:Arachidonic Acids; D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D015121:6-Ketoprostaglandin F1 alpha; D010672:Phenytoin; D015232:Dinoprostone